Sponsors

Gold Sponsors

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. HGS is poised for the market with a clinical pipeline that includes three novel products in late-stage development: Albuferon® in Phase 3 trials for hepatitis C, LymphoStat-B® in Phase 3 trials for systemic lupus, and ABthrax™ in late-stage development for inhalation anthrax. Right behind these three late-stage products is a high potential mid-stage pipeline led by the Company’s TRAIL receptor antibodies for cancer – and including a number of products to which HGS has substantial financial rights in the GSK pipeline. The HGS manufacturing capability represents a significant strategic advantage. HGS is able to produce and purify multiple protein and antibody drugs in two state-of-the-art process development and manufacturing facilities – totaling approximately 400,000 square feet and offering both small-scale and large-scale production. Unlike many pre-commercial biopharmaceutical companies, HGS has built a strong cash position that allows it to focus on advancing its lead products toward commercialization as rapidly as possible, while at the same time investing in its early- and mid-stage pipeline. HGS is committed to achieving and sustaining growth well into the future.

For more information, visit www.hgsi.com/.

McKenna Long & Aldridge LLP (MLA) is an international law firm with 475 attorneys and public policy advisors. The firm provides business solutions in the areas of environmental regulation, international law, public policy and regulatory affairs, corporate law, government contracts, intellectual property and technology, complex litigation, real estate, energy and finance. MLA’s Life Sciences and Public Health Preparedness practice is a multi-faceted resource for the biotechnology sector, including experience in emerging infectious diseases, biodefense, pandemic influenza preparedness, detection and diagnostic technologies, decision support systems for public health response, industrial biotechnology, and the burgeoning clean-tech sector. For more information, visit www.mckennalong.com

For more information, visit www.mckennalong.com/.

Silver Sponsors

Chimerix is developing antiviral therapeutics to treat life-threatening diseases. Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, adenovirus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza. The company's lead compound, CMX001, is in Phase 1 and Phase 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections among immunocompromised patients. CMX001 is also being developed as a biodefense countermeasure in the event of a smallpox release. Chimerix has advanced a second antiviral compound, CMX157, into Phase 1 clinical studies. CMX157 is being developed as a potential once-weekly nucleoside analogue against HIV infections. Building on the company’s extensive chemical library, Chimerix is also pursuing translational medicine efforts to address malaria, dengue fever and other public health needs. Chimerix has received financing from leading venture capital firms, including Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Company and Frazier Healthcare Ventures, as well as significant funding from the National Institute of Allergy and Infectious Diseases.

For more information, visit www.chimerix-inc.com/.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia.

For more information, visit www.emergentbiosolutions.com/.

GenPhar, Inc. is a biopharmaceutical company dedicated to providing vaccines that protect against infectious diseases with great socio-economic impacts worldwide.

For more information, visit www.genphar.com/.

Implicit Bioscience Pty Ltd is an immunology-focused drug development company headquartered in Brisbane, Australia with its US office located in Seattle. Its veteran founders include Ian Frazer who discovered and developed the Gardasil vaccine for HPV and cervical cancer for Merck. Implicit's team is currently developing therapies for infectious and atopic disease via modulation of the host immune response.

For more information, visit www.implicitbioscience.com/.

Osiris Therapeutics, Inc. is a company founded to commercialize stem cell products from adult bone marrow. These stem cells have demonstrated the ability to repair different types of tissues.

For more information, visit www.osiris.com.

The development of effective countermeasures to a range of potential biological and chemical weapons is PharmAthene’s primary objective. PharmAthene has recruited exceptional scientists and management to lead its programs and oversee the outsourcing of various program activities with an urgency to develop these countermeasures as rapidly as possible. In any organization, it is the people who make it all happen and that is especially true at PharmAthene. We have a unique group of seasoned, talented pharmaceutical and biotechnology professionals—each an expert in his or her respective field. Ranging from expertise in infectious diseases and genome science across the spectrum to pharmaceutical marketing and management, the depth of knowledge and collective accomplishments of our PharmAthene team is extremely impressive.

For more information, visit www.pharmathene.com/.

Pharmexa is a leading company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. Pharmexa's proprietary technology platforms are broadly applicable, allowing the company to address critical targets in cancer and chronic diseases, as well as serious infectious diseases such as HIV, influenza, hepatitis and malaria.

For more information, visit www.pharmexa.com/cms/site.aspx?p=23.

Skyline Integrated Technology Enterprises (SITE), a woman-owned small business, is an outgrowth of Kalman & Company, Inc. SITE leverages Kalman’s over twenty years experience in providing program management, acquisition, business and analytical services. Our experienced professionals provide integrated consulting services in the areas of project and contract management, proposal writing, and government cost accounting practices to companies seeking contracts with the Federal Government and those seeking general business management solutions.

For more information, visit www.skylineitent.com.

Bronze Sponsors

Iomai Corporation develops potent and safe vaccines and immune stimulants, delivered through simple adhesive patches. The company has pioneered a technology called transcutaneous immunization, which taps into the skin's immune function by targeting specialized cells that carry vaccines and immune stimulants directly to the immune system. The company¹s most advanced product is a patch-based vaccine for travelers' diarrhea, now completing Phase 2 trials. A dose-sparing patch for use with a pandemic influenza vaccine and a patch to enhance the efficacy of flu vaccination in the elderly are also in clinical testing. Finally, a needle-free flu vaccine is in preclinical development

For more information, visit www.iomai.com/.